Loes Lambrecht1, Charlotte Sleurs2,3, Veerle Labarque4,3, Catharina Dhooge5, Annouschka Laenen6, Friedl Sinnaeve7, Marleen Renard3, Anne Uyttebroeck2,3. 1. Department of Pediatrics, University Hospital Leuven, Leuven, Belgium. 2. Department of Reproduction & Regeneration, Catholic University Leuven, Leuven, Belgium. 3. Department of Pediatric Hemato-Oncology, University Hospital Leuven, Leuven, Belgium. 4. Department of Cardiovascular Science, Catholic University Leuven, Leuven, Belgium. 5. Department of Pediatric Hemato-Oncology, University Hospital Ghent, Ghent, Belgium. 6. Department of Statistics, University Hospital Leuven, Leuven, Belgium. 7. Department of Orthopedic Surgery, University Hospital Leuven, Leuven, Belgium.
Abstract
AIM: Osteosarcoma patients receive high doses of methotrexate (MTX). However, pharmacogenetic information remains limited and has mainly been investigated in leukemia so far. PATIENTS & METHODS: We investigated the link between the MTHFR C677T genotype, toxicity levels (mucositis, MTX plasma level, hematological toxicity and hepatotoxicity) and survival of 48 pediatric osteosarcoma patients. RESULTS: The TT genotype did not show more toxicity compared with the CC/CT genotype. However, plasma MTX levels were related with mucositis, but not with hematological toxicity, nor hepatotoxicity. Survival rates did not differ between homozygous and non-homozygous patients. Yet, homozygous patients had higher relapse risk. CONCLUSION: The MTHFR C667T polymorphism is not predictive for toxicity or overall survival, but could be used for relapse risk stratification.
AIM: Osteosarcomapatients receive high doses of methotrexate (MTX). However, pharmacogenetic information remains limited and has mainly been investigated in leukemia so far. PATIENTS & METHODS: We investigated the link between the MTHFRC677T genotype, toxicity levels (mucositis, MTX plasma level, hematological toxicity and hepatotoxicity) and survival of 48 pediatric osteosarcomapatients. RESULTS: The TT genotype did not show more toxicity compared with the CC/CT genotype. However, plasma MTX levels were related with mucositis, but not with hematological toxicity, nor hepatotoxicity. Survival rates did not differ between homozygous and non-homozygous patients. Yet, homozygous patients had higher relapse risk. CONCLUSION: The MTHFR C667T polymorphism is not predictive for toxicity or overall survival, but could be used for relapse risk stratification.